Do analysts rate BIOL or VVOS?

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,780.46%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BIOL or VVOS more profitable?

BIOLASE has a net margin of -41.65% compared to Vivos Therapeutics' net margin of -122.00%. BIOLASE's return on equity of -1,782.73% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Vivos Therapeutics -122.00% -2,325.64% -102.01%

Do analysts prefer VRAX or BIOL?

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 1,236.90%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, VRAX or BIOL?

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 119.97 -$5.02M N/A N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Do analysts rate BIOL or BBLG?

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or BBLG more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Bone Biologics N/A -57.87% -53.65%

Which has better earnings and valuation, BTCY or BIOL?

Biotricity has higher earnings, but lower revenue than BIOLASE. Biotricity is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biotricity $12.06M 0.09 -$14.09M -$0.14 N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is BTCY or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts rate PFSA or BIOL?

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, PFSA or BIOL?

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 8.66 -$35.82M -$5.62 thousand N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is PFSA or BIOL more profitable?

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% BIOLASE -41.65% -1,782.73% -55.31%

BIOLASE (BIOL) Competitors

Compare

BIOL vs. VVOS, VRAX, BBLG, BTCY, and PFSA

Should you buy BIOLASE stock or one of its competitors? BIOLASE's main competitors and comparable companies include Vivos Therapeutics (VVOS), Virax Biolabs Group (VRAX), Bone Biologics (BBLG), Biotricity (BTCY), and Profusa (PFSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does BIOLASE compare to Vivos Therapeutics?

BIOLASE (NASDAQ:BIOL) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

In the previous week, Vivos Therapeutics had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Vivos Therapeutics and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 equaled Vivos Therapeutics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Vivos Therapeutics	Neutral

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.11, indicating that its stock price is 511% more volatile than the broader market.

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,780.46%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

BIOLASE has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A

BIOLASE has a net margin of -41.65% compared to Vivos Therapeutics' net margin of -122.00%. BIOLASE's return on equity of -1,782.73% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Summary

Vivos Therapeutics beats BIOLASE on 8 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Virax Biolabs Group has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Virax Biolabs Group's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
BIOLASE	-41.65%	-1,782.73%	-55.31%

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	119.97	-$5.02M	N/A	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 0.3% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Virax Biolabs Group had 3 more articles in the media than BIOLASE. MarketBeat recorded 3 mentions for Virax Biolabs Group and 0 mentions for BIOLASE. Virax Biolabs Group's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
BIOLASE	Neutral

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 1,236.90%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Virax Biolabs Group beats BIOLASE on 10 of the 12 factors compared between the two stocks.

How does BIOLASE compare to Bone Biologics?

BIOLASE (NASDAQ:BIOL) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Bone Biologics has lower revenue, but higher earnings than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

In the previous week, Bone Biologics had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Bone Biologics	Neutral

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 5.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Bone Biologics	N/A	-57.87%	-53.65%

Summary

Bone Biologics beats BIOLASE on 10 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Biotricity?

Biotricity (NASDAQ:BTCY) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 1.6% of Biotricity shares are owned by company insiders. Comparatively, 0.3% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biotricity has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Biotricity has higher earnings, but lower revenue than BIOLASE. Biotricity is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.09	-$14.09M	-$0.14	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

BIOLASE has a net margin of -41.65% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
BIOLASE	-41.65%	-1,782.73%	-55.31%

In the previous week, Biotricity's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
BIOLASE	Neutral

Summary

Biotricity and BIOLASE tied by winning 5 of the 10 factors compared between the two stocks.

How does BIOLASE compare to Profusa?

Profusa (NASDAQ:PFSA) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

9.8% of Profusa shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 15.0% of Profusa shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profusa has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Profusa had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Profusa and 0 mentions for BIOLASE. Profusa's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
BIOLASE	Neutral

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Summary

BIOLASE beats Profusa on 7 of the 13 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$581K	$5.43B	$7.16B	$13.21B
Dividend Yield	N/A	1.77%	2.53%	16.37%
P/E Ratio	0.00	25.57	275.30	26.16
Price / Sales	N/A	83.34	635.97	107.50
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	N/A	5.95	11.22	6.33
Net Income	-$20.63M	$146.18M	$3.50B	$382.15M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
VVOS Vivos Therapeutics	1.8908 of 5 stars	$0.15 -1.8%	$2.80 +1,754.3%	-95.2%	$2.14M	$17.44M	N/A	268	Short Interest Increase
VRAX Virax Biolabs Group	2.8092 of 5 stars	$2.11 +3.9%	$25.00 +1,084.8%	-89.0%	$1.62M	$10K	N/A	26	News Coverage Short Interest Decrease
BBLG Bone Biologics	1.001 of 5 stars	$0.49 +1.7%	N/A	-82.7%	$1.32M	N/A	N/A	2	Gap Down
BTCY Biotricity	N/A	$0.05 +14.0%	N/A	-92.2%	$1.10M	$12.06M	N/A	46	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. VVOS, VRAX, BBLG, BTCY, and PFSA

How does BIOLASE compare to Vivos Therapeutics?

Summary

How does BIOLASE compare to Virax Biolabs Group?

Summary

How does BIOLASE compare to Bone Biologics?

Summary

How does BIOLASE compare to Biotricity?

Summary

How does BIOLASE compare to Profusa?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. VVOS, VRAX, BBLG, BTCY, and PFSA

How does BIOLASE compare to Vivos Therapeutics?

Does the media prefer BIOL or VVOS?

Which has more volatility & risk, BIOL or VVOS?

Do insiders and institutionals hold more shares of BIOL or VVOS?

Do analysts rate BIOL or VVOS?

Which has stronger valuation and earnings, BIOL or VVOS?

Is BIOL or VVOS more profitable?

Summary

How does BIOLASE compare to Virax Biolabs Group?

Is VRAX or BIOL more profitable?

Which has better valuation and earnings, VRAX or BIOL?

Do institutionals & insiders have more ownership in VRAX or BIOL?

Does the media favor VRAX or BIOL?

Do analysts prefer VRAX or BIOL?

Which has more risk & volatility, VRAX or BIOL?

Summary

How does BIOLASE compare to Bone Biologics?

Which has stronger earnings & valuation, BIOL or BBLG?

Does the media prefer BIOL or BBLG?

Do analysts rate BIOL or BBLG?

Which has more risk & volatility, BIOL or BBLG?

Do insiders and institutionals have more ownership in BIOL or BBLG?

Is BIOL or BBLG more profitable?

Summary

How does BIOLASE compare to Biotricity?

Do institutionals & insiders have more ownership in BTCY or BIOL?

Which has more risk & volatility, BTCY or BIOL?

Which has better earnings and valuation, BTCY or BIOL?

Is BTCY or BIOL more profitable?

Does the media prefer BTCY or BIOL?

Summary

How does BIOLASE compare to Profusa?

Do institutionals & insiders believe in PFSA or BIOL?

Which has more risk and volatility, PFSA or BIOL?

Is PFSA or BIOL more profitable?

Do analysts rate PFSA or BIOL?

Does the media favor PFSA or BIOL?

Which has better earnings and valuation, PFSA or BIOL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools